RecruitingNCT05610501
Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
200 participants
Start Date
May 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
In a transvaginal tru-cut biopsy, guided by ultrasound, a needle is inserted through the vaginal wall into a pelvic lesion and a few pieces of tissue are obtained for examination. This clinical trial is organized to evaluate the safety and efficacy of transvaginal tru-cut biopsy in a large group of patients with tumors in the small pelvis.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria12
- \. Following lesion criteria applicable for biopsy:
- Lesion safely accessible (no visceral or vessel interposition; in the case of a transvaginal approach no vaginal stenosis (severe atrophy - virgo - vaginismus); within reach of biopsy needle)
- Solid component present (purely cystic lesions excluded)
- \. Biopsy for research purposes, the following is applicable: Patients with a gynecological tumor eligible for participation in academic or commercial clinical trials requesting a biopsy for translational research. For the current study, which is observational, we do not intend to take additional biopsies outside routine clinical practice, but only biopsies requested for participation in other (interventional) studies on systemic treatment in gynecologic oncology.
- <!-- -->
- Suspicious primary disseminated gynecologic tumor (tumor itself or metastasis) Patients with a presumable new diagnosis of a disseminated pelvic tumor where histological confirmation of disease is necessary before the possibility to start a specific oncologic treatment and
- Are invalid candidates for primary (radical) surgery due to comorbidities or poor overall general wellbeing
- Are invalid candidates for primary (radical) surgery due to the extensive disease-spread according to imaging and/or diagnostic laparoscopy
- Suspicious primary disseminated NON-gynecologic tumor (tumor itself or metastasis)
- Patients with possible recurrence of a gynecological tumor (cervix, myometrial, endometrial, ovarian etc), where histological confirmation of disease recurrence is necessary before the possibility to start a surgical or systemic intervention.
- Patients with possible recurrence of a presumably non-gynecological tumor, where histological confirmation of disease recurrence is necessary before start of treatment.
- Solitary tumor of unknown histology localized in vaginal wall, parametria, retroperitoneum or uterine wall and can be punctured without spilling in abdominal cavity.
Exclusion Criteria2
- \- 1. Patients \< 18 years 2. Clotting defect or anticoagulation therapy, precluding a safe biopsy even with adapted therapy regimen.
- \. Vaginal or pelvic infection 4. Poor performance status contraindicating any specific oncologic treatment
Interventions
PROCEDUREUltrasound guided tru-cut biopsy
Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05610501
Related Trials
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
NCT071674331 location
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT072094497 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT0465706879 locations